Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1.
OBJECTIVE
Insulin-like growth factor (IGF)-1 has potent neuroprotective properties. We investigated the effects of intravenous administration of tissue plasminogen activator (tPA) on serum levels of IGF-1 and IGF-binding protein (IGFBP)-3 in patients with acute ischemic stroke.


METHODS
Serum levels of total IGF-1, free IGF-1, and IGFBP-3 were measured by radioimmunoassay in 10 patients with ischemic stroke treated with intravenous tPA (0.9 mg/kg body weight) and 10 untreated controls.


RESULTS
During tPA treatment, total IGF-1 and IGFBP-3 serum levels did not change, but there was an &70% increase in free IGF-1 serum levels from 0.98+/-0.25 at baseline to 1.69+/-0.18 nmol/L at the end of the 1-hour infusion (P=0.01).


CONCLUSIONS
Intravenous therapy with tPA enhances the bioavailability of IGF-1.
Wilczak
Nadine
N
Department of Neurology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Elting
Jan Willem
JW
Chesik
Daniel
D
Kema
Ido P
IP
De Keyser
Jacques
J
D000368:Aged; D000369:Aged, 80 and over; D001682:Biological Availability; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D011863:Radioimmunoassay; D020521:Stroke / Q000097:blood* / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D010959:Tissue Plasminogen Activator